Climb Bio (CLYM) Operating Expenses (2020 - 2026)
Climb Bio's (CLYM) quarterly Operating Expenses came in at $15.2 million in Q1 2026, down 33.92% YoY from $23.0 million in Q1 2025, and down 21.17% on a QoQ basis from $19.3 million in Q4 2025.
Climb Bio (CLYM) Operating Expenses (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Operating Expenses data on file, last reported at $15.2 million in Q1 2026.
- Quarterly Operating Expenses fell 33.92% year-over-year to $15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.1 million (down 41.12% YoY) and the FY2025 annual result came in at $67.9 million, down 17.24% from the prior year.
- Operating Expenses fell to $15.2 million in Q1 2026, from $19.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $56.4 million in Q2 2024 to a low of $3.0 million in Q1 2024.
- A 5-year average of $14.7 million and a median of $11.7 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 739.62% in 2024, down 87.18% in 2024.
- Tracing CLYM's Operating Expenses over 5 years: stood at $9.6 million in 2022, then sank by 46.39% to $5.1 million in 2023, then jumped by 113.02% to $10.9 million in 2024, then surged by 76.85% to $19.3 million in 2025, then slipped by 21.17% to $15.2 million in 2026.
- The last three Operating Expenses figures came in at $15.2 million (Q1 2026), $19.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 15.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.36 Mn |
| Mar 31, 2026 | 15.21 Mn |
| Dec 31, 2025 | 19.30 Mn |
| Sep 30, 2025 | 14.89 Mn |
| Jun 30, 2025 | 10.68 Mn |
| Mar 31, 2025 | 23.02 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Sep 30, 2024 | 11.73 Mn |
| Jun 30, 2024 | 56.37 Mn |
| Mar 31, 2024 | 3.01 Mn |
| Dec 31, 2023 | 5.12 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 6.71 Mn |
| Mar 31, 2023 | 23.44 Mn |
| Dec 31, 2022 | 9.55 Mn |
| Sep 30, 2022 | 8.75 Mn |
| Jun 30, 2022 | 13.70 Mn |
| Mar 31, 2022 | 13.13 Mn |
| Dec 31, 2021 | 10.70 Mn |
| Sep 30, 2021 | 9.38 Mn |